Platelet and leukocyte deposition onto metallic struts can be a crucial factor in the outcome of a coronary stenting procedure. By means of an in vitro, closed-loop circulation model, we aimed to assess blood-stent interaction patterns for a new stainless steel stent (MultiLink, Guidant Nederland BV, Nieuwegein, the Netherlands).
Methods
The effect of MultiLink (n=20) on blood cells and blood activation was studied by biochemical assays. Platelet and leukocyte adhesion to MultiLink were studied by immunofluorocytometric assays (anti-GpIIIa [CD 61] and anti-CD11b labeled antibodies, respectively), and by scanning electron microscopy. MultiLink was compared with empty circuits (n=20) and to the Palmaz Schatz stent (n=20). Experiments were performed both in the presence and in the absence of an antiplatelet agent (15 μg/mL of indomethacin).
Results
No significant effect on blood cells and blood activation was demonstrated for MultiLink. Antiplatelet treatment significantly reduced platelet adhesion to MultiLink (from 3.78±1.28 to 2.23±0.57x106 count per second [cps]/stent) but not to the Palmaz Schatz stent (from 4.11±0.31 to 5.02±1.29x106 cps/stent)(P=0.011). Leukocyte adhesion to MultiLink was significantly less than adhesion to the Palmaz Schatz stent (7.95±1.59 vs. 9.16±1.36x106 cps/stent, respectively; P=0.016), regardless of the presence of antiplatelet treatment.
Conclusions
When compared with a traditional stainless steel stent, MultiLink seems to have features of improved hemocompatibility, and single antiplatelet treatment is proposed as the treatment of choice to prevent platelet deposition.
SerruysPW, deJaegere P, KiemeneijF, . A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. The BENESTENT study. N Engl J Med1994;331:489–495.
2.
PetersonED, LanskyAJ, AnstromKJ, MuhlbaierLH, PopmaJJ, SatlerLF, LanzilottaMJ.Evolving trends in interventional device use and outcomes: Results from the National Cardiovascular Network Database. Am Heart J2000;139:198–207.
3.
MacIsaacAI, EllisSG, MullerDW, TopolEJ, WhitlowPL.Comparison of three coronary stents: Clinical and angiographic outcome after elective placement in 134 consecutive patients. Cathet Cardiovasc Diagn1994;33:199–204.
4.
KobayashiY, De GregorioJ, KobayashiN, ReimersB, AlbieroR, VaghettiM, FinciL, Di MarioC,ColomboA.Comparison of immediate and follow-up results of the short and long NIR stent with Palmaz-Schatz stent. Am J Cardiol1999;84:499–504.
5.
ColomboA, HallP, NakamuraS, AlmagorY, MaielloL, MartiniG, GaglioneA, GoldbergSL, TobisJM.Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation1995;91:1676–1688.
6.
BalconR, BeyarR, ChierchiaS, DeScheerder I, HugenholtzPG, KiemeneijF, MeierB, MeyerJ, MonassierJP, WijnsW.Recommendations on stent manufacture, implantation, and utilisation. Study Group of the Working Group on Coronary Circulation. Eur Heart J1997;18:1536–1547.
7.
MoussaI, Di MarioC,ReimersB,AkiyamaT,TobisJ,ColomboA.Subacute stent thrombosis in the era of intravascular ultrasound guided coronary stenting without anticoagulation: Frequency, predictors, and clinical outcome. J Am Coll Cardiol1997;29:6–12.
8.
De FeyterPJ, KayP, DiscoC, SerruysPW.Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. Circulation1999;100:1777–1083.
9.
GrewePH, DenekeT, MachraouiA, BarmeyerJ, MullerKM.Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen. J Am Coll Cardiol2000;35:157–163.
10.
JenkinsJS, WebelR, LaughlinMH, RowlandSM, YoklavichMF, BransonK, ParkerJL, MyersPR.The effects of intravascular stents on vasomotion in porcine coronary arteries. J Invasive Cardiol1995;7:200–206.
11.
CarterAJ, LairdJR, KufsWM, BaileyL, HoopesTG, ReevesT, FarbA, VirmaniR.Coronary stenting with a novel, stainless steel, balloon-expandable stent: determinants of neointimal formation and changes in arterial geometry after placement in an atherosclerotic model. J Am Coll Cardiol1996;27:1270–1277.
12.
MonninkSHJ, vanBoven AJ, PeelsHOJ, TigchelaarI, deKam PJ, CrijnsHJ, van OeverenW. Silicon-carbide coated coronary stents have low platelet and leukocyte adhesion during platelet activation. J Investig Med1999;47:304–310.
13.
KutrykMJB, SerruysPW.Stents: The menu. In:TopolEJ, ed.Textbook of Interventional Cardiology.Philadelphia:W.B. Saunders; 1999:533–585.
14.
MadernaP, CarusoD, TremoliE, GalliG.Differential effects of oral administrations to human volunteers of acetylsalicylic acid, sodium salicylate, and indomethacin on 12-hydroxyeicosatetraenoic acid formation by stimulated platelets. Thromb Res1988;52:197–206.
15.
HemmilaI, DakubuS, MukkalaVM, SiitariH, LovgrenT.Europium as a label in time-resolved immunofluorometric assays. Anal Biochem1984;137:335–343.
16.
GawazM, NeumannFJ, OttI, MayA, RudigerS, SchomigA.Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart1996;76:166–172.
17.
JeongMH, OwenWG, StaabME, SrivatsaSS, SangiorgiG, StewartM, HolmesDR, SchwartzRS.Porcine model of stent thrombosis: Platelets are the primary component of stent closure. Cathet Cardiovasc Diagn1996;38:38–43.
18.
KomatsuR, UedaM, NarukoT, KojimaA, BeckerAE.Neointimal tissue response at sites of coronary stenting in humans: Macroscopic, histological, and immunohistochemical analyses. Circulation1998;98:224–233.
19.
SerruysPW, vanHout B, BonnierH, LegrandV, GarciaE, MacayaC, SousaE, van der GiessenW, ColomboA, Seabra-GomesR, KiemeneijF, RuygrokP, OrmistonJ, EmanuelssonH, FajadetJ, HaudeM, KlugmannS, MorelMA.Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet1998;352:673–681.
20.
WhiteCJ, RameeSR, CollinsTJ.Elective placement of the Wiktor stent after coronary angioplasty. Am J Cardiol1994;74:274–276.
21.
BolzA, AmonM, OzbekC, HubleinB, SchaldachM.Coating of cardiovascular stents with a semiconductor to improve their hemocompatibility. Tex Heart Inst J1996;23:162–166.
22.
RogersC, EdelmanER.Endovascular stent design dictates experimental restenosis and thrombosis. Circulation1995;93:2161–2169.
23.
GarasicJM, EdelmanER, SquireJC, SeifertP, WilliamsMS,RogersC.Stent and artery geometry determine intimal thickening independent of arterial injury. Circulation2000;101:812–818.
24.
CarterAJ, ScottD, RahdertD, BaileyL, De VriesJ, AyerdiK, TurnlundT, JonesR, VirmaniR, FischellTA.Stent design favorably influences the vascular response in normal porcine coronary arteries. J Invasive Cardiol1999;11:127–134.
AlbieroR, HallP, ItohA, BlenginoS, NakamuraS, MartiniG, FerraroM, ColomboA.Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation1997;95:1145–1156.
28.
CalverAL, DawkinsKD, GrayHH, HaywoodGA, MorganJM, SimpsonIA.Intracoronary MultiLink stents: Experience in 218 patients using aspirin alone. Heart1998;80:499–504.
29.
SerruysPW,van der GiessenW, GarciaE,MacayaC, ColomboA,RutschW,VrintsC, BonnierH, MudraH, FleckE,OrmistonJ, FigullaH, Seabra-GomesR,VeldhofS.MorelMA. Clinical and angiographic results with the Multi-Link stent implanted under intravascular ultrasound guidance (WEST-2 Study). J Invasive Cardiol1998;10(suppl B):20B–27B.
30.
LincoffAM.Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Am J Cardiol1998;8236P–42P.
31.
Van BelleE,BautersC,HubertE,BodartJC,AbolmaaliK,MeuriceT, McFaddenEP,LablancheJM, BertrandME. Restenosis rates in diabetic patients: A comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation1997;96:1454–1460.
32.
EllisSG, GuettaV, MillerD, WhitlowPL, TopolEJ.Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: An analysis of results from 10,907 lesions and proposal for new classification scheme. Circulation1999;100:1971–1976.
33.
EmanuelssonH, SerruysPW,van der GiessenW,DawkinsK, RutschW,KatusH, MorelMA, VeldhofS, WijnsW, SigwartU. Clinical and angiographic results with the Multi-Link? Coronary Stent System N: The West European Stent Trial (WEST). J Invasive Cardiol1997;9:561–568.
34.
BaimDS, CutlipDE, MideiM, LinnemeierTJ, SchreiberTL, CoxD, SaucedoJF, Ki HoK,ZhangY, RobertsonLK, KuntzRE, and KereiakesD. Acute 30-day and late clinical events in the randomized parallel-group comparison of the ACS MultiLink coronary stent system and the Palmaz-Schatz stent. Circulation1997;96(suppl 1):593. Abstract.
35.
ShahPK.Plaque disruption and coronary thrombosis: New insight into pathogenesis and prevention. Clin Cardiol1997;20:38–44.
36.
van BeusekomHM, WhelanDM, HofmaSH, KrabbendamSC, van HinsberghVW, VerdouwPD, van der GiessenWJ.Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am Coll Cardiol1998;32:1109–1117.
37.
SchaferAI.Antiplatelet therapy. Am J Med1996;101:199–209.
